Anna Merlotti

Dr. Anna Merlotti


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
Cristiana Lo NigroCristiana Lo Nigro
Cristiana Lo Nigro
NDNerina Denaro
Nerina Denaro
AMAnna Merlotti
Anna Merlotti
MMMarco Merlano
Marco Merlano
For early-stage head and neck cancer (HNC), surgery (S) or radiotherapy (RT) is a standard treatment. The multidisciplinary approach, which includes multimodality treatment with S followed by RT, with or without chemotherapy (CT) or concurrent chemoradiotherapy (CRT), is required for locally advanced head and neck cancer (LAHNC). CRT improves prognosis, locoregional control (LRC), and organ function in LAHNC, compared to RT alone. Prognosis in recurrent/metastatic HNC (R/M HNC) is dismal. Platinum-based CT, combined with the anti-Epidermal Growth Factor Receptor (EGFR) antibody (Ab) cetuximab, is used in first-line setting, while no further validated options are available at progression. The complexity of disease is, in part, due to the heterogeneity of organs and functions involved and the need for a multimodality approach. In addition, the patient population (often elderly and/or patients with smoking and alcohol habits) argues for an individually tailored treatment plan. Furthermore, treatment goals – which include cure, organ, and function preservation, quality of life and palliation – must also be considered. Thus, optimal management of patients with HNC should involve a range of healthcare professionals with relevant expertise. The purpose of the present review is to 1) highlight the importance and necessity of the multidisciplinary approach in the treatment of HNC; 2) update the knowledge regarding modern surgical techniques, new medical and RT treatment approaches, and their combination; 3) identify the treatment scenario for LAHNC and R/M HNC; and 4) discuss the current role of immunotherapy in HNC.

1 November 2015 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
ASAntonio Schindler
Antonio Schindler
NDNerina Denaro
Nerina Denaro
ERElvio G. Russi
Elvio G. Russi
NPNicole Pizzorni
Nicole Pizzorni
PBPaolo Bossi
Paolo Bossi
BMBarbara Murphy
Barbara Murphy

1 December 2012 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
ERElvio G. Russi
Elvio G. Russi
RCRenzo CORVO
Renzo CORVO
AMAnna Merlotti
Anna Merlotti
DADaniela Alterio
Daniela Alterio
Pierfrancesco FrancoPierfrancesco Franco
Pierfrancesco Franco
JBJacques Bernier
Jacques Bernier

29 December 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
AMAnna Merlotti
Anna Merlotti
DADaniela Alterio
Daniela Alterio
RVRiccardo Vigna-Taglianti
Riccardo Vigna-Taglianti
AMAlessandro Muraglia
Alessandro Muraglia
LLLuciana Lastrucci
Luciana Lastrucci
GSGiuseppe Sanguineti
Giuseppe Sanguineti
Performing intensity-modulated radiotherapy (IMRT) on head and neck cancer patients (HNCPs) requires robust training and experience. Thus, in 2011, the Head and Neck Cancer Working Group (HNCWG) of the Italian Association of Radiation Oncology (AIRO) organized a study group with the aim to run a literature review to outline clinical practice recommendations, to suggest technical solutions and to advise target volumes and doses selection for head and neck cancer IMRT. The main purpose was therefore to standardize the technical approach of radiation oncologists in this context. The following paper describes the results of this working group. Volumes, techniques/strategies and dosage were summarized for each head-and-neck site and subsite according to international guidelines or after reaching a consensus in case of weak literature evidence.

9 June 2018 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
PBPierluigi Bonomo
Pierluigi Bonomo
AMAnna Merlotti
Anna Merlotti
EOE. Olmetto
E. Olmetto
ABA. Bianchi
A. Bianchi
IDIsacco Desideri
Isacco Desideri
Saverio CainiSaverio Caini
Saverio Caini
Purpose Evidence is conflicting on the prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in head and neck squamous cell carcinoma. The aim of our study was to determine the impact of semiquantitative and qualitative metabolic parameters on the outcome in patients managed with standard treatment for locally advanced disease. Methods A systematic review of the literature was conducted. A meta-analysis was performed of studies providing estimates of relative risk (RR) for the association between semiquantitative metabolic parameters and efficacy outcome measures. Results The analysis included 25 studies, for a total of 2,223 subjects. The most frequent primary tumour site was the oropharynx (1,150/2,223 patients, 51.7%). According to the available data, the majority of patients had stage III/IV disease (1,709/1,799, 94.9%; no information available in four studies) and were treated with standard concurrent chemoradiotherapy (1,562/2,009 patients, 77.7%; only one study without available information). A total of 11, 8 and 4 independent studies provided RR estimates for the association between baseline FDG PET metrics and overall survival (OS), progression-free survival (PFS) and locoregional control (LRC), respectively. High pretreatment metabolic tumour volume (MTV) was significantly associated with a worse OS (summary RR 1.86, 95% CI 1.08–3.21), PFS (summary RR 1.81, 95% CI 1.14–2.89) and LRC (summary RR 3.49, 95% CI 1.65–7.35). Given the large heterogeneity (I2 > 50%) affecting the summary measures, no cumulative threshold for an unfavourable prognosis could be defined. No statistically significant association was found between SUVmax and any of the outcome measures. Conclusion FDG PET has prognostic relevance in the context of locally advanced head and neck squamous cell carcinoma. Pretreatment MTV is the only metabolic variable with a significant impact on patient outcome. Because of the heterogeneity and the lack of standardized methodology, no definitive conclusions on optimal cut-off values can be drawn.

1 August 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa
Matteo PepaMatteo Pepa
Matteo Pepa
GMGiulia Marvaso
Giulia Marvaso
ABAlessio Bruni
Alessio Bruni
MBMichela Buglione di Monale e Bastia
Michela Buglione di Monale e Bastia
VDVittorio Donato
Vittorio Donato